FDA Reviews Drug-Eluting Stent Late Loss: More Than A Marketing Concept?
This article was originally published in The Gray Sheet
Executive Summary
Late lumen loss should be regarded strictly in the context of drug-eluting stent safety, because its value as a surrogate measure of efficacy remains unclear, FDA cautions